Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for type 2 diabetes. It enhances the body's incretin system to improve glycemic control. It is well tolerated, weight-neutral, and has a low risk of hypoglycemia, making it a useful add-on therapy to metformin or other agents.
Known hypersensitivity to sitagliptin (anaphylaxis, angioedema, Stevens-Johnson syndrome reported)1,2
History of pancreatitis (use with caution)
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.8%, weight neutral, low risk of hypoglycemia as monotherapy. 10 sources indexed (2012–2026), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Selectively and reversibly inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which normally degrades the incretin hormones GLP-1 and GIP. By prolonging incretin activity, sitagliptin enhances glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells, lowering both fasting and postprandial glucose in a glucose-dependent manner.7
Class
DPP-4 Inhibitor
Dosing
Dosing & protocol.
Common range
100 mg once daily; dose adjustment for renal impairment: 50 mg (eGFR 30–45) or 25 mg (eGFR <30) (as prescribed by your physician)
Recommended form
Oral tablet
Can be taken with or without food. No significant food interactions.
Safety
Full safety detail.
Side effects
Upper respiratory tract infection
Nasopharyngitis
Headache
Joint pain (arthralgia)
Pancreatitis (rare but serious)
Bullous pemphigoid (rare)
Contraindications
Known hypersensitivity to sitagliptin (anaphylaxis, angioedema, Stevens-Johnson syndrome reported)1,2
Sitagliptin is a DPP-4 inhibitor that lowers blood glucose by prolonging endogenous GLP-1 activity. Chromium improves insulin sensitivity. The combination is usually well tolerated when sitagliptin is the only diabetes drug, but additive glucose-lowering becomes clinically meaningful when chromium is added on top of insulin or a sulfonylurea.
Recommendation: If sitagliptin is your only diabetes medication, chromium can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether those agents need to be reduced first.
Alpha-lipoic acid improves insulin sensitivity and sitagliptin (a DPP-4 inhibitor) prolongs endogenous GLP-1 activity. On sitagliptin alone the hypoglycemia risk is low, but additive effects matter when ALA is added on top of insulin or a sulfonylurea. ALA has also rarely triggered insulin autoimmune syndrome (Hirata syndrome) with severe spontaneous hypoglycemia.
Recommendation: If sitagliptin is your only diabetes medication, ALA can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether the other agent needs a dose reduction first.
Ashraf S, Burhan M, Sarwar S et al.. Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis. Endocrinology, diabetes & metabolism. 2026
Zhang Y, Cai T, Zhao J et al.. Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2020
Du Q, Wu B, Wang YJ et al.. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Current medical research and opinion. 2013
Gerrald KR, Van Scoyoc E, Wines RC et al.. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism. 2012
Hong EG, Min KW, Chun S et al.. Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial. Diabetes, obesity & metabolism. 2025
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Sitagliptin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack